$3.73
0[0.00%]
At close: Apr 23
$3.73
0[0.00%]
PreMarket: 4:00PM EDT
Atea Pharmaceuticals
(NASDAQ:AVIR)Atea Pharmaceuticals Stock (NASDAQ:AVIR), Analyst Ratings, Price Targets, Predictions
Atea Pharmaceuticals Inc has a consensus price target of $3.33, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, JP Morgan, and SVB Leerink on August 10, 2023, March 16, 2023, and January 27, 2023. With an average price target of $4.67 between JP Morgan, JP Morgan, and SVB Leerink, there's an implied 25.11% upside for Atea Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
SVB Leerink
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Atea Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/10/2023 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | — | JP Morgan | Eric Joseph | — | Downgrade | Neutral → Underweight | Get Alert |
| 03/16/2023 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 114.48% | JP Morgan | Eric Joseph | $12 → $8 | Maintains | Neutral | Get Alert |
| 01/27/2023 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 60.86% | SVB Leerink | Roanna Ruiz | $8 → $6 | Maintains | Market Perform | Get Alert |
| 01/24/2023 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 7.24% | Morgan Stanley | Matthew Harrison | $7 → $4 | Maintains | Underweight | Get Alert |
| 08/15/2022 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 87.67% | Morgan Stanley | Matthew Harrison | $6 → $7 | Maintains | Underweight | Get Alert |
| 03/02/2022 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 114.48% | JP Morgan | Eric Joseph | $10 → $8 | Maintains | Neutral | Get Alert |
| 03/01/2022 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 141.29% | SVB Leerink | Roanna Ruiz | $10 → $9 | Maintains | Market Perform | Get Alert |
| 02/16/2022 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 168.1% | SVB Leerink | Roanna Ruiz | $11 → $10 | Maintains | Market Perform | Get Alert |
| 01/06/2022 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 87.67% | Morgan Stanley | Matthew Harrison | $14 → $7 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/18/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 194.91% | SVB Leerink | Roanna Ruiz | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/20/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 436.19% | SVB Leerink | Roanna Ruiz | — | Maintains | Outperform | Get Alert |
| 10/20/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 328.95% | JP Morgan | Eric Joseph | — | Downgrade | Overweight → Neutral | Get Alert |
| 10/05/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 1374.53% | Morgan Stanley | Matthew Harrison | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 09/09/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 1508.58% | SVB Leerink | Roanna Ruiz | — | Initiates | → Outperform | Get Alert |
| 08/18/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 891.96% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
| 06/03/2021 | AVIR | Buy Now | Atea Pharmaceuticals | $3.73 | 838.34% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Atea Pharmaceuticals (AVIR)?
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $0.00 expecting AVIR to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by JP Morgan, and Atea Pharmaceuticals downgraded their underweight rating.
When was the last upgrade for Atea Pharmaceuticals (AVIR)?
There is no last upgrade for Atea Pharmaceuticals.
When was the last downgrade for Atea Pharmaceuticals (AVIR)?
The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.